So, the natural question for Vir Biotechnology (NASDAQ:VIR) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) ...

After decades of failed attempts by corporate giants and research consortia across the globe, Kraig Biocraft Laboratories (OTCQB: KBLB) appears poised to crack biotechnology's most persistent ...

Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine ...

Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced it has filed an amended registration statement on ...

The incidence of HPV16-related cancers is rapidly increasing in the US and Europe and also increasing globally.* PDS0101 is currently being studied in the Company’s Phase 3 trial for PDS0101 + ...

MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on ...

Close to two years after AbbVie handed over $48 million for the rights to OSE Immunotherapeutics’ inflammation drug, the Big ...

Cormorant Asset Management, an investment firm focused on biotech, medtech and life science companies, is in the process of ...

We are pleased to welcome Dr. Lee and Dr. Murphy to our Board at an important time for Century as we execute with discipline and focus to bring our most differentiated iPSC-derived cell therapy ...

Biotechnology is also a vital engine of economic prosperity, generating almost 7% of U.S. private-sector GDP and supporting roughly 10 million jobs across all 50 states. The good news is that we still ...

This article is for CEOs, investors, and HR folks outside the US who want to get into or grow in the US biotech world. We'll ...

With new UK clinical trial rules landing in 2026, the EU Biotech Act on the horizon and China and Australia gaining ground, ...